Clinical trials: Sexual Transmitted Disease
HIV-1
PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
The purpose of the study is to determine the safety, tolerability and plasma pharmacokinetics (pk) (i.e., the levels of TMC558445 circulating in your blood over time) of increasing single oral doses of TMC558445 and of multiple…
- Trial name
- NCT00838760
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Cervical Cancer, Vulvar Cancer
Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
This extension study aims to evaluate the long-term protection and immune response of the bivalent HPV vaccine in women aged 18-30 who participated in a previous efficacy study (311-HPV-1003).
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN - Cervical Intraepithelial Neoplasia
- Trial name
- NCT06776055
- Testing
- HPV-16/18 vaccine
- Where
- 9 sites in China
- Volunteers
- 5,372 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
HIV Infections
QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection
This study will evaluate patient quality of life and tolerability of a HAART (highly active antiretroviral therapy) regimen containing twice-daily subcutaneous injections of Fuzeon in clinically stable, treatment-experienced…
- Trial name
- NCT00232908
- Testing
- ARV regimen, enfuvirtide [Fuzeon]
- Where
- 106 sites in United States, Puerto Rico
- Volunteers
- 361 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients
The purpose of this study is to examine the safety, tolerability, and immune response to killed-whole HIV-1 (SAV001-H) vaccine as a primary vaccination regimen in HIV infected individuals.
- Trial name
- NCT01546818
- Testing
- SAV001-H
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sumagen
HIV Infection
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
The purpose of this study is to monitor adverse events in HIV-infected children <18 years old who are exposed to Atazanavir in a real-world setting in Europe.
- Trial name
- NCT01389310
- Where
- 9 sites in Belgium, Germany and 5 more
- Volunteers
- 249 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies
The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies.
- Trial name
- NCT00002210
- Testing
- Delavirdine mesylate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Pharmacia and Upjohn
HIV
Safety and Immunogenicity Study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002)
The AELIX-002 study aims to evaluate the safety and the immunogenicity of an heterologous prime-boost regimen with DNA.HTI, MVA.HTI and ChAdOx1.HTI in early diagnosed and treated HIV-1 positive individuals, males and…
- Trial name
- NCT03204617
- Testing
- DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM), At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM)
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Aelix Therapeutics
Infection, Human Immunodeficiency Virus I, HIV Infection
Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 In HIV-1 Infected Patients
This study is a cross-sectional observational study to evaluate the prevalence of HLA-B*5701 in the European area and in major European ethnotypes.
- Conditions
- Infection, Human Immunodeficiency Virus I, HIV Infection, HIV-1 Infection
- Trial name
- NCT00481390
- Testing
- Cheek cells sample, Blood sample
- Where
- 20 sites in Finland, Ireland and 3 more
- Volunteers
- 1,110 people
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection
Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years
Human papillomavirus (HPV) infection is the most common viral infection of the reproductive tract. Up to 80%of the sexually active females and men will be infected with HPV at some point in their lives and some may be repeatedly…
- Trial name
- NCT06281119
- Testing
- Cervavac as three dose regimen, Cervavac as two dose regimen, Gardasil as three dose regimen
- Where
- 4 sites in Kenya, Mozambique and 1 more
- Volunteers
- 450 people
- Sponsor
- Serum Institute of India Pvt. Ltd.
Human Immunodeficiency Virus
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
The primary purpose of this study is to determine the pharmacokinetic properties (what the body does to maraviroc) and to determine a suitable dosing schedule of maraviroc in HIV-1 infected children and adolescents.
- Trial name
- NCT00791700
- Testing
- Maraviroc
- Where
- 41 sites in United States, Brazil and 7 more
- Volunteers
- 103 people
- Sponsor
- ViiV Healthcare
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
HIV Infections
Safety of an HIV Vaccine (AVX101) in HIV Uninfected Volunteers in the United States and South Africa
The purpose of this study is to see if different doses of an experimental HIV vaccine are safe and to study how the immune system responds to the vaccine. The vaccine will be tested in healthy, HIV uninfected volunteers.
- Trial name
- NCT00063778
- Testing
- AVX101
- Where
- 7 sites in United States, South Africa
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AlphaVax, Inc.
HIV Infection
Safety and Efficacy of T Cell Genetic Immunotherapy for HIV
This study uses autologous (one's own) CD4 T cells modified with a viral vector expressing a genetic antisense targeting HIV, this vector is called VRX496.
- Trial name
- NCT00131560
- Testing
- VRX496-Modified Autologous T cells
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- VIRxSYS Corporation
Acquired Immunodeficiency Syndrome, HIV Infection
Multicenter, Safety Study Of Maraviroc
To collect safety and tolerability data in a more diverse patient population of patients with HIV/Aids, who have limited therapeutic options.
- Trial name
- NCT00478231
- Testing
- Maraviroc
- Where
- 16 sites in Brazil
- Volunteers
- 209 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection.
- Trial name
- NCT07202546
- Testing
- VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC)
- Where
- 123 sites in United States, Argentina and 12 more
- Volunteers
- 186 people
- Sponsor
- ViiV Healthcare
Lymphoma, Non-Hodgkin, HIV Infections
Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas
To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.
- Trial name
- NCT00002003
- Testing
- Mitoxantrone hydrochloride, Etoposide
- Where
- 3 sites in United States
- Sponsor
- Lederle Laboratories
HPV Infection, HPV-Related Carcinoma
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years
To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.
- Conditions
- HPV Infection, HPV-Related Carcinoma, HPV-Related Intraepithelial Neoplasia, Genital Wart
- Trial name
- NCT06756269
- Testing
- Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, 9-HPV vaccine
- Where
- China
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
HIV Infections
A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy
The purpose of this study is to see how safe a new protease inhibitor (PI) is and how well it fights HIV infection. A PI is a drug that stops HIV from using healthy cells to make more virus.
- Trial name
- NCT00004583
- Testing
- Lopinavir/Ritonavir, Nelfinavir mesylate, Lamivudine
- Where
- 83 sites in United States, Australia and 12 more
- Volunteers
- 660 people
- Sponsor
- Abbott
Human Papilloma Virus Infection, Human Papilloma Virus
Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV
Phase II, exploratory, randomized, open, controlled and parallel groups clinical trial to evaluate the effectiveness of exploratory gel Papilocare in the repair of the cervico-vaginal mucosa with lesions caused by HPV.
- Conditions
- Human Papilloma Virus Infection, Human Papilloma Virus, Cervix Lesion
- Trial name
- PALOMA (NCT04002154)
- Testing
- Papilocare vaginal gel
- Where
- 9 sites in Spain
- Volunteers
- 134 people
- Sponsor
- Procare Health Iberia S.L.
Cervical Cancers, Vulvar Cancer
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
This study will evaluate the immunogenicity and tolerability of V503 (a multivalent human papillomavirus [HPV] L1 virus-like particle [VLP] vaccine) in preadolescent and adolescent participants between 9 and 15 years old and…
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, Genital Lesions
- Trial name
- NCT00943722
- Testing
- V503
- Volunteers
- 3,074 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC